What is West Nile Virus
West Nile virus (WNV) is a single-stranded RNA flavivirus transmitted primarily through bites of infected Culex mosquitoes that causes neuroinvasive disease in less than 1% of infections but remains the leading cause of mosquito-borne illness in the United States. 1, 2
Virology and Classification
WNV belongs to the Flaviviridae family and shares antigenic similarities with Japanese encephalitis and St. Louis encephalitis viruses 1. The virus is neurotropic, meaning it has a predilection for invading the nervous system 2, 3.
Transmission
The virus spreads through several routes:
- Primary route: Bites from infected Culex species mosquitoes, which maintain the virus in a mosquito-bird-mosquito transmission cycle 2, 4
- Rare routes: Blood transfusion, organ transplantation, transplacental transmission, perinatal exposure, breastmilk, and percutaneous or conjunctival exposure 2
Birds serve as the natural reservoir hosts, with over 300 species capable of infection 5.
Geographic Distribution and Epidemiology
WNV was originally isolated in 1937 from Uganda's West Nile province and is widely distributed across Africa, Europe, Australia, and Asia 6. The virus entered North America in 1999 through New York City and has since become the most common mosquito-borne virus on the continent 3, 4.
From 2014 to 2023, the US averaged 1,298 neuroinvasive disease cases and 129 deaths annually 2. The largest county-level outbreak occurred in Arizona in 2021, with 1,487 cases and 101 deaths 2.
Clinical Spectrum
The infection presents across a wide spectrum:
- 80% of infections: Completely asymptomatic 2
- 20% of infections: West Nile fever (febrile illness) 2
- <1% of infections: Neuroinvasive disease including meningitis, encephalitis, and acute flaccid myelitis 2
High-Risk Populations
Mortality risk increases dramatically with age and immunosuppression:
- Overall neuroinvasive disease mortality: 10% 2
- Age ≥70 years: 20% mortality 2
- Hematologic malignancies: 30-40% mortality 2
- Solid organ transplant recipients: 30-40% mortality 2
- Patients receiving B-cell-depleting monoclonal antibodies: 30-40% mortality 2
Among hospitalized patients, 30-40% require discharge to long-term care facilities, and more than 50% experience persistent sequelae including fatigue, weakness, myalgia, memory loss, and depression 2.
Diagnosis
For patients with fever or neurologic symptoms during summer and fall months in endemic areas, test serum and/or cerebrospinal fluid for WNV-specific IgM antibodies 2. Follow with confirmatory neutralizing antibody testing when cross-reacting flavivirus exposure is possible, presentation is atypical, death occurs, or unusual transmission modes are suspected 2.
In severely immunocompromised patients, reverse transcription-PCR testing is often more sensitive than IgM testing 2, 7.
Treatment and Prevention
No evidence-based therapies or human vaccines exist for WNV disease 2, 3. Management relies entirely on supportive care.
Prevention strategies include:
- Using EPA-registered mosquito repellents on skin and clothing 1
- Wearing protective clothing 1
- Limiting outdoor exposure from dusk to dawn when mosquitoes are most active 1
- Community-level mosquito control measures 2
Blood Supply and Transplant Safety
Since WNV screening of the US blood supply began in 2003, only 14 transfusion-transmitted cases have been reported 2. From 2002 to 2023,14 clusters of WNV transmission through solid organ transplantation were identified in the US and Italy 2.
Climate Change Impact
Global warming is expanding WNV's geographic range northward, with milder winters and longer warm seasons increasing mosquito activity and enabling year-round transmission 5, 8. Europe reported 1,200 annual cases in 2024, with spread noted into Germany and The Netherlands 5.